Setmelanotide for Treatment of Acquired Hypothalamic Obesity
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Diabetes & Endocrinology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial
Lancet Diabetes Endocrinol 2024 Apr 29;[EPub Ahead of Print], CL Roth, C Scimia, AH Shoemaker, M Gottschalk, J Miller, G Yuan, S Malhotra, MJ AbuzzahabFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.